Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: lower sodium Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Not applicable Interventional

Sodium Lowering Vascular Effects Trial

NCT05388032
View directory record Official record
Conditions
Endothelial Dysfunction, Vascular Stiffness, Left Ventricular Hypertrophy, Left Ventricular Dysfunction
Interventions
Sodium Reduction Intervention
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo, mRNA-1273.214
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months to 11 Years
Enrollment
11,942 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 4 Interventional Results available

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

NCT02970669
View directory record Official record
Conditions
Heart Failure, Reduced Ejection Fraction
Interventions
sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

NCT04384523
View directory record Official record
Conditions
Ascites Hepatic
Interventions
OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo
Drug · Other
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Withdrawn Phase 4 Interventional

Hyaluronic Acid Gels for Lower Lid Retraction

NCT01838252
View directory record Official record
Conditions
Ectropion
Interventions
Hyaluronic acid, Saline
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

NCT02973477
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Dapagliflozin, Glimepiride
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Beverage Volume, Glycerol Concentration, and Sodium Concentration on Fluid Balance in Healthy Euhydrated Men and Women at Rest

NCT06854471
View directory record Official record
Conditions
Fluid Balance
Interventions
Placebo beverage, kiwi-strawberry flavor, Electrolyte solution without glycerol beverage 1, Electrolyte solution without glycerol beverage 2, Electrolyte solution without glycerol beverage 3, Electrolyte solution with glycerol beverage 1, Electrolyte solution with glycerol beverage 2, Electrolyte solution with glycerol beverage 3, Base with glycerol, no electrolytes beverage 1, Base with glycerol, no electrolytes beverage 2, Base with glycerol, no electrolytes beverage 3
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Bradenton, Florida • St. Petersburg, Florida • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Results available

Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

NCT02145260
View directory record Official record
Conditions
Intra-dialytic Hypotension
Interventions
Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate), Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

NCT00607373
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Charlotte, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 3, 2026, 11:36 AM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional

Lowering Salt Intake in Chronic Kidney Disease: A Pilot Randomized Crossover Trial

NCT00974636
View directory record Official record
Conditions
Kidney Disease
Interventions
Low Salt Diet, Usual Salt Diet
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

NCT00531843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
fondaparinux sodium, sequential compression devices
Drug · Device
Lead sponsor
Mary Knudson, M.D.
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antecedent Metabolic Health and Metformin Aging Study

NCT04264897
View directory record Official record
Conditions
Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
40 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Role of Opioidergic Systems in Breathing Based Analgesia

NCT03419858
View directory record Official record
Conditions
Pain
Interventions
Mindfulness Meditation, Placebo Meditation, Slow-Breathing, Naloxone, Saline
Behavioral · Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

NCT01603459
View directory record Official record
Conditions
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Doral, Florida • Indianapolis, Indiana • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

NCT03169959
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional

Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension

NCT05393232
View directory record Official record
Conditions
Hypertension
Interventions
Dietitian-Assisted DASH groceries, Self-directed shopping
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403
View directory record Official record
Conditions
Healthy
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Orthodontic Varnish Microbiology Study

NCT04528134
View directory record Official record
Conditions
Dental Caries, Dental Plaque, Dental White Spot
Interventions
Extended Contact RMGI (Resin-modified Glass Ionomer) Varnish, 5% Sodium Fluoride Varnish
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 27 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 3, 2026, 11:36 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

NCT04818034
View directory record Official record
Conditions
Cystinuria
Interventions
Dapagliflozin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 3, 2026, 11:36 AM EDT